| Name | Title | Contact Details |
|---|---|---|
Abhimanyu Verma |
Senior Vice President and Chief Technology Officer | Profile |
Adam Molyneaux |
Chief Architect | Profile |
Sergei Yakneen |
Chief Information Officer | Profile |
Sergei Yakneen |
Chief Technology Officer | Profile |
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.
BioTech Insight is a Pebble Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients lives.
Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics` lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.